Two of them were detected in stool samples of CRC patients with sensitivities and specificities > 80%: GADD45B and MYC. Combined with ITGA6 as the IGM score, they allowed an increase in the specificity of up to 97% while in combination with the iFOBT, sensitivity and specificity for the detection of lesions were at 92 and 97% for stage I-IV CRC and 98 and 97% for stage II-III CRC. The gene discussed is MYC; the disease is colorectal carcinoma.